Cerus Corporation (CERS) has a MoatMap StockRank of 68/100 based on Quality (43/100), Value (38/100), and Momentum (71/100) factor scores. The current signal is BUY. Cerus Corporation focuses on blood safety. Despite its niche medical technology, it has historically struggled to achieve consistent profitability and high ROIC, making it a poor fit for our quality-first compounding criteria.
Cerus Corporation is a biomedical products company focused on blood safety, developing and commercializing the INTERCEPT Blood System, a proprietary technology designed to inactivate a broad spectrum of pathogens in transfused blood components. Its competitive moat lies in its patented technology, offering a critical safety enhancement in transfusion medicine with significant regulatory approvals and growing adoption by blood centers globally. Cerus is a niche leader, driving innovation in blood component safety with a unique and effective solution.
| Price | $2.58 |
| Market Cap | $585M |
| Price/Book | 8.28 |
| Return on Equity | -15.4% |
| Return on Invested Capital | -5.7% |
| Debt/Equity | 142.57 |
| Gross Margin | 53.0% |
| Operating Margin | -0.7% |
| Revenue Growth | 24.1% |
| Free Cash Flow | $2M |
Cerus Corporation operates in the Medical Devices industry, part of the Healthcare sector (United States).